Emergent BioSolutions Inc.EBSNYSE
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | -10.37% |
| Q3 2025 | 8.00% |
| Q2 2025 | -17.22% |
| Q1 2025 | 65.93% |
| Q4 2024 | -34.06% |
| Q3 2024 | -57.80% |
| Q2 2024 | 116.56% |
| Q1 2024 | -48.64% |
| Q4 2023 | 92.16% |
| Q3 2023 | -41.15% |
| Q2 2023 | -36.12% |
| Q1 2023 | -13.40% |
| Q4 2022 | 11.37% |
| Q3 2022 | -19.92% |
| Q2 2022 | 13.58% |
| Q1 2022 | -44.10% |
| Q4 2021 | 67.34% |
| Q3 2021 | 1.43% |
| Q2 2021 | -6.86% |
| Q1 2021 | -11.76% |
| Q4 2020 | -29.50% |
| Q3 2020 | 76.20% |
| Q2 2020 | 12.18% |
| Q1 2020 | -32.01% |
| Q4 2019 | 17.60% |
| Q3 2019 | -16.43% |
| Q2 2019 | 38.61% |
| Q1 2019 | -11.35% |
| Q4 2018 | 40.54% |
| Q3 2018 | 49.80% |
| Q2 2018 | -15.12% |
| Q1 2018 | 2.06% |
| Q4 2017 | 25.84% |
| Q3 2017 | -12.01% |
| Q2 2017 | 25.76% |
| Q1 2017 | -24.49% |
| Q4 2016 | -0.26% |
| Q3 2016 | -2.53% |
| Q2 2016 | 6.90% |
| Q1 2016 | 2.92% |